Avrion Therapeutics AG

Avrion Therapeutics is a spin-off from EPFL developing precision gene therapy solutions to address genetically defined neurological disorders. Gene therapies can provide benefit through modulation of gene function and typically require a single administration of the treatment. The company has a patent-protected Adeno Associated Virus (AAV)-based gene therapy platform resulting from more than 10 years of research at the Brain Mind Institute & Campus Biotech Gene Therapy Platform (EPFL). AAV gene therapies are evolving, and ongoing a switch to engineered synthetic promoters allowing to target safely a defined subset of cells, which is exactly what makes Avrion Therapeutics unique.